Moving the needle in fusion has never been easier
MagnetOs Easypack Putty
MagnetOsTM Easypack Putty is our easiest to mold formulation. Designed for speed and efficiency, MagnetOs Easypack Putty is out of the box ready, while maintaining its presence during irrigation or joint compression during arthrodesis.
This formulation delivers all the benefits of our potent NeedleGripTM surface technology – which grows bone even in soft tissue* without added cells or growth factors.1-3†‡
Simply dispense MagnetOs Easypack Putty from the accompanying syringe, mold the product into the desired shape, and place into the extremity where joint fusion is desired or in voids resulting from trauma in the foot and ankle or upper extremity.
Harnessing the immune system
MagnetOs Easy Pack Putty is capable of polarizing macrophages from the M1 pro-inflammatory to the M2 pro-healing phenotype, which is known to influence bone growth through secretion of proteins such as BMP-2. MagnetOs has been shown in pre-clinical studies to form bone even in soft tissue* without added cells or growth factors.2,3,4†‡ These features combine to make MagnetOs an active player in providing predictable joint arthrodesis and traumatic reconstructions of the extremity.
Ready-to-use
MagnetOs Easypack Putty comes ready-to-use in an open-ended syringe for instant application into the palm of your hand. No further preparation is needed – making this the most efficient formulation in our portfolio.
Designed to stay put
You don’t need to compromise on efficacy for the sake of perioperative performance. MagnetOs Easypack Putty has been formulated to maintain its presence during compression across the joint, as well as resist irrigation and minimize post-operative graft migration.6 This is a putty that stays put.
Clinical Storyboard
MagnetOs Easypack Putty in a First Metatarsal-Phalangeal (MTP) Fusion
Dr. Anthony (Bobby) Ndu is an orthopedic surgeon at Penn Medicine. Dr. Ndu treats a wide range of foot and ankle conditions, with a particular interest in hind foot reconstruction and flat foot correction.
In the interactive Clinical Storyboard below, one of Dr. Ndu’s patients is followed before and after fusion using MagnetOs Easypack Putty for a first MTP fusion.
Demographics
63-year-old female
BMI 30.2
Past medical history:
- Bilateral hallux rigidus
- Bilateral tarsal tunnel syndrome
- Bilateral hip osteoarthritis
- Prior bilateral cheilectomy of the first MTP joint
Preoperative Exam
Clinical observations:
- Bilateral hallux rigidus
- Dorsal midfoot bone spurs
- Lumbar spine disc issues and hip osteoarthritis contributing to gait abnormalities
- Persistent bilateral pain, stiffness, numbness in the first MTP joints and midfoot
- Pain radiating dorsally and plantarly towards the arch
Conservative treatment:
- Physical therapy, orthodics, reduction in activity, and tarsal tunnel injections
- Continued pain, stiffness, and poor response
Pre-operative X-rays
Pre-operative X-rays
X-rays show prior cheilectomy without acute changes or fracture.
Degenerative changes are apparently including irregularity of the left first proximal phalanx.
Degeneration could be related to osteoarthritis or erosion in the setting of inflammatory arthropathy.
Calcaneal enthesopathy and first metatarsophalangeal joint osteoarthritis are observed.
Procedure
- Minimally Invasive (MIS) left first MTP arthrodesis
- 1.5cc MagnetOs Easypack Putty
- 2 cannulated 4.0 PECA screws§
Intra-operative X-Ray
Intra-operative X-Ray
Intra-operative AP and oblique non-weight bearing fluoroscopy images of the left foot demonstrate interim fusion of the first MTP joint with a two-screw construct and 1.5 cc of MagnetOs Easypack Putty
2 Week X-Rays
2 Week X-Rays
Pain: Minimal to moderate. Using Tylenol; waxing/waning swelling
Mobility/Ambulation: Weight-bearing as tolerated on the heel; using a hard sole shoe and cane
Surgical observations:
Three views of the left foot status post first MTP fusion shows anatomic bony alignment with hardware in good position.
There is evidence of MagnetOs in the first MTP space with no migration present.
6 Week X-Rays
6 Week X-Rays
Pain: Well-controlled
Mobility/Ambulation: Weight-bearing as tolerated; transitioned to sneakers with a carbon fiber insert; advised to begin a four-week trial of life before considering physical therapy
Surgical observations:
Three views of the left foot status post first MTP fusion shows anatomic bony alignment with hardware in good position. No acute radiographic osseous abnormalities are present.
There is maturation of the fusion mass with increased mineralization across the joint.
Moderate first IP joint osteoarthritis is visible with spurring of the first metatarsocuneiform joint dorsally.
Dorsal calcaneal enthesopathy and mild pes planovalgus are observed in the hind/mid-foot.
3 Month X-Rays
3 Month X-Rays
Pain: Well-controlled, minimal residual numbness and swelling through the hallux
Physical exam: Solid and stable at the first MTP with attempted Shuck motion; all incisions clean dry and intact.
Mobility/Ambulation: Advised to bear weight as tolerated, can discontinue carbon fiber insert by the end of the month, and begin impact activity
Surgical observations:
Continued bony union at the first MTP with two screws spanning the joint which was stable with interval increase in osseous growth compared to previous imaging.
7 Month X-Ray
7 Month X-Ray
Pain: No discomfort in the left foot
Physical exam: Solid and stable at the first MTP with attempted Shuck motion; sensation decreased in light touch at the tip of the hallux
Mobility/Ambulation: Full weight-bearing
Surgical observations:
Continued bony union at the first MTP with two screws spanning the joint which was stable.
There has been continued osseous growth with complete bony fusion.
MagnetOs Mechanism of Action
1. Polarize
Circulating immune cells (monocytes) differentiate into macrophages that are subsequently polarized, by the submicron needle-shaped features of MagnetOs’ Needlegrip surface.
As a result, they become the pro-healing, anti-inflammatory M2 macrophage phenotype.†2,6
2. Regenerate
In natural bone homeostasis, it is well established that M2 macrophages play a critical role.
M2 macrophages communicate with local stem – and progenitor cells via secretion of regenerative signaling factors, including osteoactivin and BMP-2.6,12,13
These signaling factors induce mesenchymal stem cells to migrate, proliferate, and differentiate into osteoblasts that lay down osteoid.6,13-15
Endothelial cells are stimulated to form capillaries that deliver nutrients and yet more osteogenic cells to the site of repair.6,13
3. Propagate
Non-unions tend to happen in the core of large-span defects, as seen in spinal fusions.
NeedleGrip propagates bone in this core region – by interacting directly and indirectly with circulating osteogenic cells – rather than only from the outside-in via creeping edge repair.†‡2-5
Product code Volume (cc) Granule size (mm)
703-048-US 1.5 1-2
703-050-US 2.5 1-2
703-051-US 5 1-2
703-053-US 10 1-2
703-054-US 15 1-2
Want to learn more about MagnetOs Easypack Putty?
Book your own appointment with one of our scientific experts.
Nothing to display.
1. Duan, et al. eCM. 2019;37:60-73.
2. Van Dijk, et al. eCM. 2021;41:756-73
3. Van Dijk, et al. J Immunol Regen Med. 2023;19:100070.
4. Please refer to the Instructions for Use (IFU) MagnetOs Easypack Putty (US) for a full list of indications, contraindications, precautions and warnings.
5. Data on file.
* In large animal models.
† Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com/eifu.
‡ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.